Official launch of Biotech Connection Singapore & OneStart Europe
Biotech Connection Singapore Launch
Biotech Connection, formerly known as Oxbridge Biotech Roundtable (OBR), is a non-profit, cross-institutional platform that seeks to promote biotech entrepreneurship in Singapore. Biotech Connection aims to foster conversations between academic scientists with industry professionals and investors with a vision to create a global network of academic innovators from across disciplines and act as the seed-bed for the next generation of biotech entrepreneurs. To ignite Biotech Connection’s vision for Singapore, we are honoured to have Prof. Steven Myint and A/Prof. Tan Sze Wee as our distinguished panel speakers, discussing the future of Biotech entrepreneurism in Singapore.
OneStart Europe launch – Open to entries from Asia this year!
OBR together with SR One would like to invite you to participate in OneStart - the world's largest biotech business competition / accelerator program. The mission of the competition is to help you to realize your innovative ideas advancing healthcare. If you have an idea for a new therapeutic, medical device, novel cell culture method, health IT solution, or even if you do not have your own idea, but have the scientific or business know-how to help someone else realise their business, apply to the OneStart competition. The winner will receive SGD200k, free lab space in bioincubator ‘Stevenage Biocatalyst’ near London, and ongoing business advice. For more details see:http://www.oxbridgebiotech.com/onestart/
OneStart launch in Singapore is co-organised by Biotech Connection Singapore.
6:30 – 7:00 PM Registration
7:00 – 7:15 PM Biotech Connection Launch
7:15 – 7:45 PM OneStart Europe Launch
7:45 – 8:30 PM "The Entrepreneur’s Rule Book" discussion
8:30 – 9:30 PM Networking & Refreshments
Prof Steven Myint MD PhD is one of our SAB members. He is a physician with global experience in health and biomedical management. He is currently a Senior fellow to A*STAR, and consultant to its commercialization arm, ETPL. He is also Adjunct Professor at Duke-NUS in the Center for Technology, Enterprise and Development. In these capacities he is involved in the commercialization of biomedical and bio-engineering research. He is also Chairman of Inex Private Ltd (Singapore), Chairman of Plexpress Oy and Inc (Finland), non-executive director of Aplagon Oy and Primex Oy (Finland) and non-executive director of Lipid Genomics (Boston). He was a founding partner of Ukko Partners, a Finnish Vigo accelerator, and a partner in Pharma Capital, the Palo Alto based venture fund. Until recently he was also executive chairman of Green Signal Bio, which he developed into one of India’s largest vaccine manufacturers. Since starting his first spinout in 2005, he has been involved in the development of over 30 SME’s in life sciences and created over $1billion value for shareholders.
Assoc Prof Tan Sze Wee MBBS MBA is currently the Deputy Executive Director of Biomedical Research Council, A*STAR, the Programme Director of A*STAR’s Healthcare and Lifestyle Programme Office and Chairman of the Singapore Stanford Biodesign steering committee. He is also an Adjunct Associate Professor at Duke-NUS Graduate Medical School Singapore and the Honarary Treasurer of the Singapore Medical Association (SMA). A/Prof Tan has over 15 years of experience in the local and regional healthcare and medical device industry. He was formerly the Asia-Pacific Associate Regional Medical Director for Mead Johnson Nutritionals, a divisional of Bristol-Myers Squibb Company from 1997 to 2001 and also served as the MD and CEO of Rockeby Biomed Limited, a Singapore-based healthcare company.